News

Justin Schleede reaches onto a black lab bench to pick up a tray of small plastic tubes.

"These are saliva samples as well as blood," says Schleede, a geneticist who runs Herasight Inc.'s lab in Morrisville, N.C. "We also...

This is the 15th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. You can read the first part here. The series...

"If proven to be safe, we believe preventive gene editing could be one of the most important health technologies of...

WILLIAM BATESON, a foundational figure in the science of genetics at the turn of the last century, once recounted the...

By Mary Papenfuss, Huffpost | 07.16.2021

In a new political low in Texas, the Republican-dominated state Senate has passed a bill to eliminate a...

By Cormac Sheridan, Nature | 07.15.2021

A recent study has identified another potential hazard for developers of genome editing therapies based on CRISPR–Cas9. The double-strand DNA...

sickle cells
By Ted W. Love, STAT | 07.15.2021

Covid-19 laid bare the long-standing vulnerability of minority and low-income communities in U.S. society and its health system even as...

a lab mouse sitting in a gloved hand
By Megan Molteni, STAT | 07.15.2021

The tiny clump of mouse cells didn’t look like an ovary. For one thing, it was much smaller, microscopic. And...

Peter Mills
By Peter Mills, Nuffield Council on Bioethics | 07.14.2021

In 2019, the World Health Organization convened an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of...

disabled sign
By s.e. smith, The Nation | 07.14.2021

Imagining better worlds can help us improve our own, but literary and cinematic utopias often exclude those who don’t fit...

Cleveland Clinic Miller Family Pavilion
By Pam Belluck, New York Times | 07.14.2021

The Cleveland Clinic Miller Family Pavilion
HealthMonitor, CC BY-SA 4.0,
via Wikimedia Commons

In a striking reflection of concern...

Biogen logo
By Jonathan Saltzman, Boston Globe | 07.13.2021

At least half-a-dozen private health insurers in some of the nation’s largest states are balking at covering Biogen’s controversial drug...